Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E; Cooperative Group for the Treatment of Digestive Tumors. Sastre J, et al. Among authors: aranda e. J Clin Oncol. 2005 May 20;23(15):3545-51. doi: 10.1200/JCO.2005.03.004. J Clin Oncol. 2005. PMID: 15908665 Clinical Trial.
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Díaz-Rubio E, et al. Among authors: aranda e. J Clin Oncol. 2007 Sep 20;25(27):4224-30. doi: 10.1200/JCO.2006.09.8467. Epub 2007 Jun 4. J Clin Oncol. 2007. PMID: 17548839 Clinical Trial.
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours. Martinez-Balibrea E, et al. Among authors: aranda e. Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025. Epub 2008 Apr 28. Eur J Cancer. 2008. PMID: 18448328 Clinical Trial.
Treatment recommendations for metastatic colorectal cancer.
Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Aranda E, et al. Clin Transl Oncol. 2011 Mar;13(3):162-78. doi: 10.1007/s12094-011-0636-7. Clin Transl Oncol. 2011. PMID: 21421461 Review.
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E, Gómez A, Cabrera E, Queralt B, Gómez MJ, Guasch I, Etxeberría A, Alfaro J, Campos JM, Reina JJ, Aranda E. Benavides M, et al. Among authors: aranda e. Clin Colorectal Cancer. 2012 Sep;11(3):200-6. doi: 10.1016/j.clcc.2012.01.003. Epub 2012 Mar 14. Clin Colorectal Cancer. 2012. PMID: 22421001 Clinical Trial.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Garcia-Alfonso P, et al. Among authors: aranda e. BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y. BMC Cancer. 2015. PMID: 25925749 Free PMC article. Clinical Trial.
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E. Llovet P, et al. Among authors: aranda e. Mol Diagn Ther. 2015 Dec;19(6):397-408. doi: 10.1007/s40291-015-0165-0. Mol Diagn Ther. 2015. PMID: 26341080
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Santos C, et al. Among authors: aranda e. Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16. Mol Cancer Ther. 2017. PMID: 28626084 Free article.
448 results